Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Palatin Technologies, Inc. Common Stock (NY:PTN)

0.5350 -0.0450 (-7.76%)
Streaming Delayed Price Updated: 12:37 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Palatin Technologies, Inc. Common Stock

< Previous 1 2 3 4 Next >
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN)
Via AB Newswire
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight
Palatin's study shows co-administering bremelanotide with tirzepatide led to greater weight loss than tirzepatide alone, with further analysis ongoing. 
Via Benzinga
Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)
Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN) 
Via News Direct
Exposures Product Safety
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus
Palatin's PL8177 showed promising ulcerative colitis trial results, with strong clinical response rates. FDA granted orphan status to its obesity drug PL7737. 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For February 13, 2025
Via Benzinga
A Look Ahead: Palatin Techs's Earnings Forecast
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Earnings Preview: Palatin Techs
Via Benzinga
Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)
Via AB Newswire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
On Friday, there are stocks with unusual volume. Let's take a look.
Unusual volume stocks in Friday's session 
Via Chartmill
Thursday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Get insights into the top gainers and losers of Monday's after-hours session.
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions 
Via News Direct
Exposures Product Safety
PTN Stock Earnings: Palatin Techs Misses EPS for Q3 2024
PTN stock results show that Palatin Techs missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Palatin Technologies And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested... 
Via Benzinga
Topics Stocks
Exposures US Equities
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data
Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically significant efficacy in pain reduction and secondary symptoms. PL9643... 
Via Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets
Palatin Technologies' results from PL9643 MELODY-1 Phase 3 trial for dry eye disease. The co-primary endpoints and secondary endpoints did not reach statistical significance. 
Via Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.52% to 38,770.83 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
The 3 Best Penny Stocks to Buy in February 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies. 
Via InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot. 
Via InvestorPlace
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
These penny stocks have triple-digit upside as 2024 brings easing monetary policy and economic normalization. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.